congtrats small mile stone @ $20-00 with more to come.
Printable View
A lot of excitement this week $17 up to $20
China trade figures, Bubs quarter and I assume everyone is expecting an ATM quarterly very soon.
What about the March lockdowns and the Chinese lockdowns in Feb March?
But then again people stockpiled, so the figures could be good.
..... and over $20 she goes!
Fab day for holders!
Another week and we're into 20s range and since there wasn't any update from company, I'm picking probably looking at an update in May with forecast for whole of FY20.
my only regret is that I didn't buy more :)
Where does everyone see this share price going in say 3-5 years? I'd assume the growth at some point will start to slow.
In the last 5 years ATM's SP has gone from .50c to $20. That sort of phenomenal growth (as a small cap company becomes a big cap company) has been great for some investors, however, it is unusual (not only in NZX or ASX terms but worldwide) and it is unlikely to be repeated in the next 5 years.
Where will the SP go from here? If you are into TA, just take the 5 year chart and extend the trend lines. Alternately, take the attached table and start adding in your projections. I suspect it will take at least 3 years for the SP to double from $20 to $40 (still a good return and even better if you are working from a .50c baseline ) but as always, DYOR and take responsibility for your own decisions.
Attachment 11360
Attachment 11361
If you are wanting to repeat the success of the 50c investors in ATM in the next 5 years, I suspect you are going to have to find another small cap company with great management, great product, and great prospects..... when you find that company let me know!!
This Geoffrey guy sure has the Midas touch
http://nzx-prod-s7fsd7f98s.s3-websit...000/321191.pdf
Leftfield pretty good on his forecast revenues
Trading update today....... here's the link.
Notwithstanding this uncertainty, we anticipate revenue for FY20 in the range of $1,700 million to $1,750 million.
Full year EBITDA margin is now anticipated to be above that advised in February and in the range of 31% to 32%. This assumes that planned marketing activity for FY20 of $200 million, weighted to 2H20, will be fully expended prior to year-end.
Our 2H20 EBITDA margin is therefore expected to be higher than previously anticipated. This is primarily a result of:
• Higher revenue, and hence gross margin, from higher margin nutritional products, in part due to consumer pantry stocking in 3Q20 compared to expectations;
• Favourable impact arising from exchange rate movement in USD:NZD impacting on China segment revenue and earnings; and
• Lower than expected costs for travel, and other costs as a consequence of a delay in planned recruitment, due to COVID-19 restrictions.
Nicely balanced update IMHO.
Share price $25 by end of May